Apolipoprotein Proteomic Profiling for the Prediction of Cardiovascular Death in Patients with Heart Failure

Lemesle, Gilles; Chouraki, Vincent; Groote, P. De; Turkieh, Annie; Beseme, Olivia; Drobecq, Hervé; Amouyel, Philippe; Lamblin, Nicolas; Bauters, Christophe; Pinet, Florence

doi:10.1002/prca.202000035

Cited by 5 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interactions between different apolipoproteins have also described in the pathogenesis of human CHF [64]. All proteins that showed significant changes in this study seemed to have interactions by one or more chemical pathways.…”

Section: Discussionsupporting

confidence: 55%

Platelet proteome changes in dogs with congestive heart failure

et al. 2020

View full text Add to dashboard Cite

Background Platelets play a central role in the development of cardiovascular diseases and changes in their proteins are involved in the pathophysiology of heart diseases in humans. There is lack of knowledge about the possible role of platelets in congestive heart failure (CHF) in dogs. Thus, this study aimed to investigate the changes in global platelet proteomes in dogs with CHF, to clarify the possible role of platelets in the physiopathology of this disease. Healthy-dogs (n = 10) and dogs with acute CHF due to myxomatous mitral valve disease (MMVD, n = 10) were used. Acute CHF was defined based on the clinical (increased respiratory rate or difficulty breathing) and radiographic findings of pulmonary edema. Dogs Blood samples were collected into tubes with acid-citrate-dextrose, and platelet-pellets were obtained by centrifuge and washing steps. Platelet-proteomes were identified using LC-MS based label-free differential proteome expression analysis method and matched according to protein database for Canis lupus familiaris. Results Totally 104 different proteins were identified in the platelets of the dogs being 4 out of them were significantly up-regulated and 6 down-regulated in acute CHF dogs. Guanine-nucleotide-binding protein, apolipoproteins (A-II and C-III) and clusterin levels increased, but CXC-motif-chemokine-10, cytochrome-C-oxidase-subunit-2, cathepsin-D, serine/threonine-protein-phosphatase-PP1-gamma-catalytic-subunit, creatine-kinase-B-type and myotrophin levels decreased in acute CHF dogs. These proteins are associated with several molecular functions, biological processes, signaling systems and immune-inflammatory responses. Conclusion This study describes by first time the changes in the protein composition in platelets of dogs with acute CHF due to MMVD. Our findings provide a resource for increase the knowledge about the proteome of canine platelets and their roles in CHF caused by MMVD and could be a tool for further investigations about the prevention and treatment of this disease.

show abstract

Section: Discussionsupporting

confidence: 55%

Platelet proteome changes in dogs with congestive heart failure

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Interactions between different apolipoproteins have also described in the pathogenesis of human CHF (64). All proteins that showed signi cant changes in this study seemed to have interactions by one or more chemical pathways.…”

Section: Discussionsupporting

confidence: 55%

Platelet proteome changes in dogs with congestive heart failure

Levent

Kocatürk

Akgun

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Platelets play a central role in the development of cardiovascular diseases and changes in their proteins are involved in the pathophysiology of heart diseases in humans. There is lack of knowledge about the possible role of platelets in congestive heart failure (CHF) in dogs. Thus, this study aimed to investigate the changes in global platelet proteomes in dogs with CHF, to clarify the possible role of platelets in the physiopathology of this disease. Healthy-dogs (n=10) and dogs with acute CHF due to myxomatous mitral valve disease (MMVD, n=10) were used. Acute CHF was defined based on the clinical (increased respiratory rate or difficulty breathing) and radiographic findings of pulmonary edema. Dogs Blood samples were collected into tubes with acid-citrate-dextrose, and platelet-pellets were obtained by centrifuge and washing steps. Platelet-proteomes were identified using LC-MS based label-free differential proteome expression analysis method and matched according to protein database for Canis lupus familiaris. Results: Totally 107 different proteins were identified in the platelets of the dogs being 4 out of them were significantly up-regulated and 6 down-regulated in acute CHF dogs. Guanine-nucleotide-binding protein, apolipoproteins (A-II and C-III) and clusterin levels increased, but CXC-motif-chemokine-10, cytochrome-C-oxidase-subunit-2, cathepsin-D, serine/threonine-protein-phosphatase-PP1-gamma-catalytic-subunit, creatine-kinase-B-type and myotrophin levels decreased in acute CHF dogs. These proteins are associated with several molecular functions, biological processes, signaling systems and immune-inflammatory responses.Conclusion: This study describes by first time the changes in the protein composition in platelets of dogs with acute CHF due to MMVD. Our findings provide a resource for increase the knowledge about the proteome of canine platelets and their roles in CHF caused by MMVD and could be a tool for further investigations about the prevention and treatment of this disease.

show abstract

“…Higher levels of plasma apoC1 were found in patients who died from cardiovascular diseases when compared to those who did not. This difference was observed whereas triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol levels after three years of follow-up were similar between the two groups [ 47 ]. These pejorative correlations between plasma apoC1 and atherosclerosis or cardiovascular death were observed in contexts that are critical for atherosclerosis and cardiovascular events, i.e.…”

Section: Apoc1 and Atherosclerosismentioning

confidence: 99%

“…The serum concentration of apoC1 is about 60 mg/L in normolipidemic subjects [3,13,[42][43][44]. ApoC1 is mainly measured by enzyme-linked immunosorbent assay (ELISA) [13,45,46] but the use of mass spectrometry is becoming more and more widespread [47]. ApoC1 is mainly associated with HDL and VLDL in humans [4,48,49].…”

Section: Plasma Levels and Distribution Of Apoc1 Between Lipoproteinsmentioning

confidence: 99%

Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review

Rouland

Masson

Lagrost

et al. 2022

Cardiovasc Diabetol

View full text Add to dashboard Cite

Apolipoprotein C1 (apoC1) is a small size apolipoprotein whose exact role is not totally clarified but which seems to modulate significantly the metabolism of lipoproteins. ApoC1 is involved in the metabolism of triglyceride-rich lipoproteins by inhibiting the binding of very low density lipoproteins (VLDL) to VLDL-receptor (VLDL-R), to low density lipoprotein receptor (LDL-R) and to LDL receptor related protein (LRP), by reducing the activity of lipoprotein lipase (LPL) and by stimulating VLDL production, all these effects leading to increase plasma triglycerides. ApoC1 takes also part in the metabolism of high density lipoproteins (HDL) by inhibiting Cholesterol Ester Transfer Protein (CETP). The functionality of apoC1 on CETP activity is impaired in diabetes that might account, at least in part, for the increased plasma CETP activity observed in patients with diabetes. Its different effects on lipoprotein metabolism with a possible role in the modulation of inflammation makes the net impact of apoC1 on cardiometabolic risk difficult to figure out and apoC1 might be considered as pro-atherogenic or anti-atherogenic depending on the overall metabolic context. Making the link between total plasma apoC1 levels and the risk of cardio-metabolic diseases is difficult due to the high exchangeability of this small protein whose biological effects might depend essentially on its association with VLDL or HDL. The role of apoC1 in humans is not entirely elucidated and further studies are needed to determine its precise role in lipid metabolism and its possible pleiotropic effects on inflammation and vascular wall biology. In this review, we will present data on apoC1 structure and distribution among lipoproteins, on the effects of apoC1 on VLDL metabolism and HDL metabolism and we will discuss the possible links between apoC1, atherosclerosis and diabetes.

show abstract

Apolipoprotein Proteomic Profiling for the Prediction of Cardiovascular Death in Patients with Heart Failure

Cited by 5 publications

References 37 publications

Platelet proteome changes in dogs with congestive heart failure

Platelet proteome changes in dogs with congestive heart failure

Platelet proteome changes in dogs with congestive heart failure

Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review

Contact Info

Product

Resources

About